IRIS
D'AMICO, EMANUELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.742
EU - Europa 2.429
AS - Asia 2.305
SA - Sud America 444
AF - Africa 386
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.315
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.598
SG - Singapore 1.315
RU - Federazione Russa 977
CN - Cina 640
IE - Irlanda 437
IT - Italia 435
BR - Brasile 377
CI - Costa d'Avorio 298
UA - Ucraina 192
VN - Vietnam 137
CA - Canada 124
DE - Germania 94
GB - Regno Unito 68
IN - India 59
SN - Senegal 54
SE - Svezia 41
FR - Francia 37
KR - Corea 37
AR - Argentina 26
BD - Bangladesh 25
FI - Finlandia 25
NL - Olanda 24
PL - Polonia 22
CH - Svizzera 16
UZ - Uzbekistan 14
ZA - Sudafrica 13
EC - Ecuador 12
MX - Messico 12
AT - Austria 10
IQ - Iraq 10
TR - Turchia 10
HK - Hong Kong 9
JP - Giappone 9
ES - Italia 8
LT - Lituania 8
PK - Pakistan 8
VE - Venezuela 8
LB - Libano 7
AU - Australia 6
CO - Colombia 6
HR - Croazia 6
SA - Arabia Saudita 6
BE - Belgio 5
CZ - Repubblica Ceca 5
GR - Grecia 5
BJ - Benin 4
NG - Nigeria 4
NP - Nepal 4
PE - Perù 4
PY - Paraguay 4
TN - Tunisia 4
HU - Ungheria 3
JM - Giamaica 3
KE - Kenya 3
MA - Marocco 3
UY - Uruguay 3
BO - Bolivia 2
CL - Cile 2
DZ - Algeria 2
ID - Indonesia 2
IL - Israele 2
IR - Iran 2
LK - Sri Lanka 2
LU - Lussemburgo 2
RO - Romania 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BT - Bhutan 1
BY - Bielorussia 1
CR - Costa Rica 1
EG - Egitto 1
EU - Europa 1
GT - Guatemala 1
JO - Giordania 1
KH - Cambogia 1
KI - Kiribati 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PW - Palau 1
SV - El Salvador 1
Totale 10.315
Salva come PNG Salva come JPEG
Città #
Dallas 844
Singapore 749
Santa Clara 657
Chandler 562
Moscow 450
Dublin 435
Abidjan 298
Ashburn 234
Chicago 201
Jacksonville 196
Boardman 175
Cambridge 119
Lawrence 119
Andover 116
Houston 111
Nanjing 101
Los Angeles 92
Beijing 91
Toronto 80
Catania 79
Hefei 75
Civitanova Marche 63
Des Moines 57
Dakar 54
Wilmington 49
Seoul 37
Nanchang 34
Grafing 33
Shenyang 32
Bremen 31
Ho Chi Minh City 30
San Mateo 29
Hanoi 28
Saint Petersburg 28
São Paulo 28
Ottawa 27
Dong Ket 26
Council Bluffs 25
Buffalo 22
Hebei 22
New York 22
The Dalles 22
Changsha 21
Columbus 21
Jiaxing 19
Bari 18
Lappeenranta 18
San Francisco 17
Washington 16
Tianjin 15
Chennai 14
London 14
Warsaw 14
Amsterdam 11
San Jose 11
Seattle 11
Siracusa 11
Denver 10
Jinan 10
Johannesburg 10
Phoenix 10
Pune 10
Belo Horizonte 9
Montreal 9
Naples 9
Norwalk 9
Orem 9
Padova 9
Poplar 9
Rio de Janeiro 9
Zhengzhou 9
Kunming 8
Mumbai 8
Ningbo 8
Redondo Beach 8
Tokyo 8
Ann Arbor 7
Brasília 7
Den Haag 7
Guarulhos 7
Palermo 7
Porto Alegre 7
Rome 7
Stockholm 7
Zola Predosa 7
Brooklyn 6
Edinburgh 6
Goiânia 6
Guangzhou 6
Helsinki 6
Hong Kong 6
Juiz de Fora 6
Manchester 6
Messina 6
Quito 6
Redwood City 6
Zagreb 6
Biên Hòa 5
Dhaka 5
Elk Grove Village 5
Totale 7.035
Salva come PNG Salva come JPEG
Nome #
Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD) 160
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update 159
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort 148
Management of dysphagia in multiple sclerosis: current best practice 145
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 144
Comparison of genioglossus muscle activity and efficiency of dexmedetomidine or propofol during drug-induced sleep endoscopy in patients with obstructive sleep apnea/hypopnea syndrome 136
Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience 134
An update on the safety of treating relapsing-remitting multiple sclerosis 131
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience 125
Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS 124
Cognitive dysfunction in multiple sclerosis. A population based study in Catania, Sicily 122
Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study 119
Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. 117
Can new chemical therapies improve the management of multiple sclerosis in children? 116
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review 115
Lack of association between Toxocara canis and multiple sclerosis: A population-based case-control study 114
Association between dietary intake and function in amyotrophic lateral sclerosis 114
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 113
Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience 112
CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset 112
An update on the pharmacological management of pain in patients with multiple sclerosis 112
CCSVI and MS. A population-based case-control study in Catania, Sicily. 111
Morfometria delle strutture del tronco encefalico in pazienti affetti da atassia spino-cerebellare tipo 2 (SCA 2): indicatore diagnostico e riabilitativo? 111
Approccio clinico e possibilità di trattamento nella SLA 110
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience 109
Post-Cerebrovascular Stroke and Early Dysphagia Assessment: A Systematic Review 104
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 104
Validation of the DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis 103
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 103
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 102
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 102
Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis 100
Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion 100
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. 99
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 99
Clinical Evolution of Relapsing Remitting Late Onset Multiple Sclerosis: A Nine Year Follow-Up Study 98
Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life 97
Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis Patients 97
Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study 96
Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla 96
Pharmacoeconomics of synthetic therapies for multiple sclerosis 95
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 94
Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis 93
Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives 93
Palliative care in progressive multiple sclerosis 92
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience 92
Oral drugs in multiple sclerosis therapy: An overview and a critical appraisal 91
Toxoplasma gondii and multiple sclerosis: a population-based case–control study 91
Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study 91
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 91
Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study 89
Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria 89
La sindrome disesecutiva nel Mild Cognitive Impairment: aspetti clinici e possibilità riabilitative 88
Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment 88
Wegener’s Granulomatosis Presenting as An Intracranial Hypertension Syndrome Treated with High Dose of Cyclophosphamide 87
Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study 86
Depressive symptoms correlate with disability and disease course in multiple sclerosis patients: An Italian multi-center study using the Beck Depression Inventory 86
Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide 83
Cognitive impairment in clinical isolated syndrome suggestive of multiple sclerosis: association with brain imaging and retinal nerve fiber layer thickness 83
Disease trajectory in secondary progressive multiple sclerosis: a ten years follow-up study 83
Primary cerebral vasculitis 83
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives 82
Real-life impact of early interferonβ therapy in relapsing multiple sclerosis 80
Disability may influence patient willingness to partecipate in decision making on first-line therapy in multiple sclerosis 79
Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study) 78
Treatment options of cognitive impairment in multiple sclerosis 78
Metal/metalloid levels in cerebrospinal fluid in the bulbar-and spinal-onset amyotrophic lateral sclerosis 75
Detrimental effects of cyclophosphamide on seminal cells in men whith MS 74
Cyclophosphamide induction therapy versus conventional therapy: a pilot study 74
The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study 74
Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs 73
Long term follow-up of combination therapy with inf-eta and cyclophosphamide relapsing-remitting MS patients 73
Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study 72
Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience 72
Personalized Therapy in Multiple Sclerosis: state of art and future perspectives 69
WII may improve physical abilities in multiple sclerosis: a randomized single blind study 69
Genetic burden of common variants in progressive and bout-onset multiple sclerosis 68
To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question 68
Conventional brain MRI could be a predictor of post partum relapse in multiple sclerosis 67
Cognitive-motor dual-task interference:A systematic review of neural correlates 67
Gender related thyroid dysfunction and autoimmunità in multiple sclerosis patients treated with interferon-beta 66
Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study 66
Negative prognostic impact of MRI spinal lesion in the early stages of relapsing-remitting multiple sclerosis 66
Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis 65
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 64
Multidisciplinary approach of amyotrophic lateral sclerosis: a centre experience 64
Treatment in worsening multiple sclerosis patients: new drugs are better than older ones? 64
Real-world comparison of Dimethyl-fumarate and teriflunomide in treatment-naive and non responders patients with relapsing remitting multiple sclerosis: preliminary data of a multicenter, prospectie study 64
Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial 64
Risk factors in multiple sclerosis: a population-based case-control study in Sicily. Background and methods 63
Untreated relapsing remitting multiple sclerosis (RR-MS) patients. A single centre exprerience 62
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 62
The effects of different cognitive and motor tasks on the dual task cost of walking in multiple sclerosis: a case-control study 61
Multiple Sclerosis and CCSVI: A Population-Based Case Control Study 61
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience 61
Review: Patient-reported outcomes in multiple sclerosis care 60
Prevalence of patient-reported disphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire) 59
Prevalence of pain in multiple sclerosis: a multicenter italian study 58
Psychological and social findings of patients with early multiple sclerosis or clinically isolated syndrome 58
The association of CCSVI and MS is not a risk factor for cognitive impariment in MS 58
Totale 9.119
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.842
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.842
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021214 0 0 0 0 0 9 30 5 65 15 47 43
2021/2022799 79 130 15 8 125 4 123 22 52 5 41 195
2022/20231.609 128 84 30 164 154 282 4 281 386 6 68 22
2023/2024704 34 182 37 19 23 119 21 64 4 31 117 53
2024/20252.438 30 366 150 128 493 354 75 94 198 231 172 147
2025/20263.637 305 214 981 371 835 931 0 0 0 0 0 0
Totale 10.549